Loading patent…
AssigneeThe Administrators of the Tulane Educational Fund
InventorsDavid H. COY, Jerome L. MADERDRUT, Min LI
Estimating the term…
This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.
An isolated compound having formula (I), or a pharmaceutically acceptable salt thereof:
A polypeptide having at least 90% sequence identity to a sequence selected from SEQ ID NOs:
A method for treating, managing, or preventing a disease selected from age-related neurodegenerative disease, a central nervous system disorder, Huntington's disease or other CAG codon repeat expansion disease, a retinal disease, an autoimmune disease, keratoconjunctivitis sicca caused by autoimmune diseases or LASIK surgery, type II diabetes, sepsis caused by a bacteria and/or a virus, an acute or chronic cardiovascular disease, an acute or chronic renal diseases, an acute or chronic pulmonary disease, systemic hypertension, a hematological cancer, an eating disorder, an acute or chronic liver disease, osteoporosis, pre-eclampsia, cell and solid organ transplantation, a cognitive disorder, acquired immunodeficiency syndrome (AIDS) dementia complex, aging of the central nervous system, and a disease caused in part by premature in-frame stop codons that result in the synthesis of truncated nonfunctional proteins, said method comprising administering to a subject in need thereof an effective amount of one or more PACAP-like compounds or a pharmaceutically acceptable salt thereof.
A method for the localization, diagnosis, or treatment of a disseminated cancer or a metastatic tumor in a subject comprising administering an effective amount of a conjugate comprising one or more PACAP-like compounds or a pharmaceutically acceptable salt thereof coupled to one or more radionuclides.
A method of producing a conjugate comprising coupling one or more radionuclides or small molecules to one or more PACAP-like compounds.
A method for targeting delivery of a therapeutic or anticancer agent to a specific cell or tissue of a subject comprising administering to said subject an effective amount of a conjugate comprising one or more PACAP-like compounds, or a pharmaceutically acceptable salt thereof, coupled to one or more small molecules.
Dependencies are inferred from the claim text.